| 摘要 |
<p>The invention relates to an intravaginal drug delivery device for administration to a female mammal of certain 17β-oestradiol precursors at a substantially constant rate for a period of at least three weeks. The 17β-oestradiol precursor is a 17β-oestradiol moiety in which the, or each, hydroxyl group of the 17β-oestradiol moiety is blocked by a blocking group, which blocking group is readily removed from the 17β-oestradiol moiety in vivo. The 17β-oestradiol precursor must either have a solubility in liquid silicone of not less than 0.1 mg/100 ml or have a standard k value of not less than 0.1 νg/day/mm. The 17β-oestradiol precursor must also have a solubility in distilled water of not less than 1νg/100 ml.</p> |
